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Erythroid leukemia (ERL or AML-M6) is an uncommon subtype of acute myeloid leukemia, the clinical, morphological, and
genetic behavior of which needs further characterization. We analyzed a homogeneous group of 23 de novo AML-M6 patients
whose bone marrow cells showed complex karyotypes. We also analyzed eight leukemia cell lines with erythroid phenotype,
performing detailed molecular cytogenetic analyses, including spectral karyotyping (SKY) in all samples. The main features are:
(1) A majority of patients (56%) had hypodiploidy. Loss of genetic material was the most common genetic change, especially
monosomies of chromosome 7 or 18, and deletions of chromosome arm 5q. Taken together, 87% of the cases displayed
aberrations involving chromosome 5 or 8. (2) We describe a novel, cryptic, and recurrent translocation, t(11;19)(p11.2;q13.1).
Another translocation, t(12;21)(p11.2;q11.2), was found to be recurrent in a patient with ERL and in the K562 cell line. (3)MLL
gene rearrangements were detected in 20% of cases (three translocations and three amplifications) and, overall, we defined
52 rearrangements (excluding deletions) with a mean of 2.3 translocations per patient. (4) Of the structural aberrations, 21%
involved chromosomes 11 and 19. Most of the rearrangements were unbalanced; only 13 reciprocal translocations were
observed. The general picture of chromosomal aberrations in cell lines did not reflect what occurred in patient samples.
However, both primary samples and cell lines shared three common breakpoints at 19q13.1, 20q11.2, and 21q11.2. This is the
first molecular cytogenetic description of the karyotype abnormalities present in patients with ERL. It should assist in the
identification of genes involved in erythroleukemogenesis. © 2003 Wiley-Liss, Inc.
De novo erythroleukemia (ERL) is a rare type of
acute myeloid leukemia (AML), representing
2–7% of de novo AML cases. Because of its heter-
ogeneous nature, ERL has posed difficulties in its
precise classification. Most authors agree that two
main subtypes exist, according to the WHO classi-
fication of acute erythroid leukemias: (1) erythro-
leukemia (erythroid/myeloid), M6 acute leukemia
according to the FAB criteria, in which mixed gran-
ulocytic (20% myeloblasts) and erythroblastic
cellular components are present; and (2) pure ery-
throid leukemia with erythroblasts constituting
more than 80% of the marrow cells, with no signif-
icant myeloblastic component (Bennett et al., 1985;
Goldberg et al., 1998; Mazzella et al., 1998; Jaffe et
al., 2001; Domingo-Claros et al., 2002; Park et al.,
2002).
In contrast to other types of acute leukemia, no
specific cytogenetic or molecular markers are avail-
able for ERL for classification or prognostic pur-
poses (Cuneo et al., 1990; Olopade et al., 1992;
Kwong, 1998). About 70% of de novo ERL cases
show chromosome abnormalities (Cuneo et al.,
1990; Olopade et al., 1992; Goldberg et al., 1998).
In fact, 378 different abnormal karyotypes have
been recorded in the Mitelman Database of Chro-
mosome Aberrations in Human Cancer (http://
cgap.nci.nih.gov/Chromosomes/Mitelman) (Mitel-
man et al., 2002). Other than a high frequency of
loss or partial deletions of chromosomes 5 and/or 7,
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or trisomy 8, which are commonly found in myelo-
dysplasias and several subgroups of AML, specific
genetic abnormalities have not been recurrently
found in ERL. The most commonly identified
karyotypes in ERL reflect a great complexity (fre-
quently with more than three rearrangements), and
a lack of recurrent breakpoints (other than those
affecting chromosome 5 or 7). More powerful mo-
lecular cytogenetic tools are now available, such as
fluorescence in situ hybridization (FISH), compar-
ative genomic hybridization (CGH), and spectral
karyotyping (SKY), which can help in identifying
the genetic changes that take place in ERL. We
used molecular cytogenetics to study a series of
homogeneously defined de novo ERLs, with com-
plex karyotypes, as well as eight erythroid leuke-
mia cell lines. We found several recurring distinc-
tive and novel genetic features of this subtype of
leukemia.
We studied 23 patients, 10 male and 13 female,
whose ages ranged from 1 to 85 years, with a me-
dian of 69 years. All samples were collected at
diagnosis. The clinical history of previous hemato-
logic disorders and/or chemotherapy or exposure to
other known genotoxic agents was ruled out in
every case. Morphological classification criteria
were applied according to the WHO proposal (Jaffe
et al., 2001). Erythroleukemia (erythroid/myeloid)
was defined by the presence of 50% erythroid
precursors in the entire nucleated cell population
and 20% myeloblasts in the non-erythroid popu-
lation; pure erythroid leukemia: 80% of marrow
cells of the erythroid lineage with no evidence of a
significant myeloblastic component. All slides were
reviewed centrally by some of the authors. We also
analyzed eight leukemia cell lines with erythroid
phenotype, irrespective of the type of leukemia
from which they were derived. Five cell lines were
derived from chronic myeloid leukemia (CML) in
blast crisis, SAM-1 (provided by J. Cossman), AP-
217 (provided by R. Berthier), K-562 (in-house),
HEL-R (provided by T. Papayannnopoulou), and
LAMA 84 and KU812 (provided by J. Goldman).
Two cell lines were derived from AML-M6:
KMOE-2 (from the Deutsche Sammlung von Mik-
roorganismen und Zellkulturen, Germany) and
TF-1 (in-house). The cells lines were cultured,
according to their respective requirements, and
they were harvested after 2 hr of exposure to Col-
cemid, for standard cytogenetic procedures.
All samples had a complex aberrant karyotype at
diagnosis. We considered a karyotype complex
when three or more clonal chromosome abnormal-
ities were identified. Conventional cytogenetics
was performed on bone marrow samples after di-
rect and/or short-term culture without mitogens.
Metaphase cells were prepared from all samples.
G-banding analysis was performed by standard pro-
cedures. Karyotypes were described according to
the ISCN (Mitelman, 1995). After conventional
cytogenetic analysis, slides were prepared from the
fixative-stored material and hybridized using the
SKY method according to the manufacturer’s pro-
tocol (Applied Spectral Imaging, Migdal Ha-Emck,
Israel). Images were acquired with an SD300 Spec-
tra cube (Applied Spectral Imaging) mounted on a
Zeiss Axioplan microscope using a custom-de-
signed optical filter, SKY-1 (Chroma Technology,
Brattleboro, VT). For each case, 8–30 metaphase
cells were captured and analyzed. Breakpoints cor-
responding to the chromosome abnormalities were
assigned based on the corresponding DAPI band-
ing and G-banded karyotype of the same cells. An
abnormality or breakpoint was considered as recur-
rent if it was identified in two or more different
cases by G-banding or SKY. A whole chromosome
painting (WCP) probe for chromosome 19, telo-
meric 19p and 19q FISH probes (Appligene Oncor,
France), and BCR/ABL and MLL FISH probes (Vy-
sis, Downers Grove, IL) were used to define the
involvement of these genes or chromosome re-
gions. Hybridizations were performed according to
the manufacturer’s protocols.
All 23 patients were selected based on their
fulfillment of the WHO criteria for ERL and the
presence of complex karyotypes at diagnosis as
detected by G-banding. Bone marrow morpholog-
ical analysis showed that two thirds of the patients
had trilineage dysplasia. All but two cases (cases 18
and 22) were classified as erythroleukemia (ery-
throid/myeloid), according to the WHO classifica-
tion criteria (Table 1). The clinical course of the
patients was poor, with a mean survival of only 4.3
months (range, 1–25 months). To characterize the
chromosome profile completely, we performed
spectral karyotyping in all cases. The SKY karyo-
types are given in Table 1. All data discussed
below make reference to the SKY analysis.
Hypodiploidy seems to be a rather common ge-
netic feature of ERL. Thirteen cases (56%)
showed hypodiploid karyotypes. The proportion of
hypodiploid cases (excluding cases with only
monosomy 7) has been reported (Mitelman et al.,
2002) to range between 2% for M5 and 11% for M1,
with ERL showing a significantly higher ratio of
38%. In our series, which included only de novo
cases, 70% of the cases showed chromosome 5
monosomy or 5q deletions; trisomy 8, either alone
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or with other abnormalities, was seen in 52% of the
cases; monosomy or 7q deletions were observed in
43% of the patients. Taken together, 87% of the
cases displayed aberrations involving chromosome
5 or 8, and 91% of the cases demonstrated an
abnormality of chromosome 5, 7, or 8.
Two recent papers have demonstrated that hy-
podiploidy and loss of genetic material are the most
frequent finding in AML with complex karyotypes
(Mrozek et al., 2002; Schoch et al., 2002). Those
series both included de novo and therapy-related
cases; the most frequent whole-chromosome losses
were monosomies 7 and 18, and the most frequent
interstitial deletions involved 5q, 17p, 12p, and
20q. In our series of de novo ERL cases, we ob-
served a nearly identical profile, suggesting a com-
mon genetic pattern of chromosomal aberrations in
myeloblast proliferation.
Fifty-two rearrangements (excluding deletions)
were defined in our series, with a median of 2.3 per
case (range, 0–10), of which 13 were balanced
translocations. SKY analysis refined the vast major-
ity of structural aberrations. None has been re-
ported in the Mitelman Database (Mitelman et al.,
2002) or in the most recently reported ERL cases
(Mrozek et al., 2002; Schoch et al., 2002). In fact,
TABLE 1. Clinical and Molecular Cytogenetic Description of the Abnormal Clones Found in de Novo ERL Patients Using GTG
Banding and SKY Techniques
Case
no.
Sex/
age Survivala Dysplasiab SKY karyotype
1 M/73 1 Tri 3758,XX,der(3)t(3;21)(q11.2;q11.2),del(5)(q12q33),8,der(8)t(8;11)(p21;p11.2)t(8;12)(q22;
q13),t(11;19)(q23;p13.3),der(12)t(12;18)(q24;q11.2),der(16)t(3;16)(?;p11.2),der(18)t(3;
18)(?;q21),der(19)ins(19;17)(p13.1;?)t(3;19)(q11.2;p13.3),r(11)2amp(MLL)
2 M/77 1 Tri 4446,XX,del(5)(q13q33),7,19
3 F/63 5 Tri 4648,XX,del(5)(q13q33),8,der(11)t(6;11)(p15;?),13,18,19,21
4 F/57 2 Tri 44,XY,t(1;7)(q32;q32),7,8,9,13,17,20,212
5 M/69 3 Tri 4555,XX,X,1,2,del(5)(q13q33),6,8,11,r(11)2amp(MLL),14,22
6 M/67 5 Tri 4548,XX,inv(3)(q21q26),del(5)(q13q33),7,8,del(10)(q24),der(11)t(11;19)(p11.2;
q13.1),del(12)(p11),del(13)(q14),der(16)t(11;16)(q23;q22),der(17)ins(17;3)(q22;
?),der(19)t(11;19)(p15;p13.1),20,r(?)
7 M/68 4 Ery 4546,Y,der(X)t(X;13)(p22.1;q22),i(3)(q10),del(5)(q22),inv(6)(p23q12),der(13)t(2;9;13)(?;?;
q22),der(16)t(1;16)(?;q21–22),19,21
8 M/65 3 Tri 4445,XY,del(5)(q13),7,8,del(12)(p13),der(16)t(2;16)(?;q?),20
9 M/70 4 Tri 6165,XYY,12,2,3,4,5,der(5)t(5;14;16)(q13;q13;
?),inv(6)(p23q12)2,7,82,16,19,der(19)t(19;20)(q13.1;
p11.2)2,212,22,der(22)del(22)(q11)2
10 M/71 8 Tri 4245,X,del(X)(q13),1,del(5)(q13q31),del(5)(p13),6,7,8,t(11;19)(p11.2;
q13.1),hsr(12)(p13),t(13;14)(p11;q11)c,der(15)t(13;15)(q24;?),17,t(18;21)(p11.2;
q11.2),r(19)
5154,X,del(X)(q13),1,del(5)(q13q31),del(5)(p13),6,i(7)(q10),8,t(11;19)(p11.2;
q13.1),t(12;15)(p13;q22),t(13;14)(p11;q11),14,15,202,21,r(19)
11 F/69 1 Tri 5152,XX,8,del(10)(q24),del(11)(p15),3,der(16)t(7;16)(?;q24)
12 F/76 6 Ery 3542,XX,r(3),5,der(7)t(6;7)(?;q22),t(7;10)(p15;q22),9,10,der(11)t(9;11)(p12;
p15),del(13)(q22),17,18
13 F/59 14 Tri 45,XX,der(1;19)(p32;p13.1),t(3;9)(q21;q13),del(5)(q13q31),t(14;
21)(q10,q10),17,19,r(11)amp(MLL)
14 F/72 5 Ery 45,XX,5,der(7)t(7,9)(q32;q13),der(9)t(9,19)(q13;q13.1),18,21,dmin,amp(c-MYC)
15 M/82 1 Tri 4648,XY,der(2)t(2;3)(q31;?),4,7,8
16 F/69 3 Tri 44,XX,t(1;12)(q42;p13),t(2;15)(q31;q24),der(5)t(5;17)(q13;q22),t(6;18)(q27;q21),7,17
17 F/71 24 Tri 46,XX,del(1)(p13),7,der(11)t(1;11)(?;q23),ins(12;1)(q24;?),der(14)t(1;14)(?;q13),20
18 F/1 7 Eryc 49,XX,inv(X)(p22.1q13),5,8,18 [15]
19 F/37 25 Ery 46,X,t(X;11)(q13;p15),del(14)(q23q32) [20]
20 F/85 7 E/M 4647,XX,5,8,del(20)(q12)
21 M/50 25 Ery 4447,XY,der(4)t(4;7)(p12;q21),del(5)(q13),der(8)t(3;8)(?;q24)2,der(12)t(12;21)(p13;
q11.2),der(14)t(7;14)(?;q32)
22 F/76 8 E/M 4547,XX,del(5)(q13q31),7,del(7)(q11.2),der(7)t(7;9)(q11.2;?),der(7)t(7;20)(q11.2;
q11.2),der(16)t(1;16)(?;q22),der(18)t(7;18)(q22;q21)
23 F/71 6 Tri 4647,XX,t(X;9;22)(?;q34;q11.2),8,i(17)(q10)
aSurvival is given in months.
bLineage involvement: Tri, erythroid–myeloid–megakaryoblastic; Ery: erythroid; E/M: erythroid–myeloid.
cPure erythroid leukemia. M6b type, according to the WHO classification.
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the karyotypes of ERL have generally been char-
acterized by the presence of numerous chromo-
somal rearrangements, without specific and recur-
rent breakpoints. Only the t(3;5) translocation has
been seen in several cases of M6 (10 of 378 cases),
but the exact breakpoints involved are not identical
(Kwong, 1998; Mitelman et al., 2002). We did not
find this rearrangement in our series. As in other
acute myeloid leukemias with complex karyotypes,
unbalanced rearrangements led to the net loss of
genetic material in several segments, mainly 5q,
7q, 17p, and 12p. Although it has been reported
that some 5q or 7q deletions can be redefined as
unbalanced translocations, we did not find such
deletions.
A novel and cryptic recurrent balanced translo-
cation was found in cases 6 and 10 of our study.
The t(11;19)(p11.2;q13.1) has not been reported
previously for any kind of malignancy. The trans-
location was detected only by SKY, whereas it had
been described as a deletion on 11p by conven-
tional cytogenetics. We characterized the translo-
cation by WCP and FISH hybridizations and used
telomeric probes for chromosome 19 (Fig. 1A–D).
The lack of sufficient biological material from the
patients precludes specific molecular genetic stud-
ies; however, both chromosomal regions, 11p11.2
and 19q13.1, harbor genes that regulate the cell
cycle or cell proliferation (e.g., KAI1, HPTP eta,
MLL2, and others) (Honda et al., 1994; Huntsman
et al., 1999; Silver et al., 1999; Verma et al., 1999).
We found three translocations with breakpoints
at 11q23, the chromosomal site of the MLL gene:
t(11;19)(q23;p13.3), t(11;16)(q23;q22), and t(1;
11)(?;q23) in cases 1, 6, and 17, respectively. By
FISH analysis, we detected that MLL was rear-
ranged in these three cases. The first two translo-
cations have been reported in small series of
AML-M6 that occurred after exposure to DNA-
damaging agents (Groupe Franc¸ais de Cytoge´ne´t-
ique He´matologique, 1984; Moorman et al., 1998).
Our cases had no antecedents of such exposure,
although, because the MLL gene is recurrently in-
volved in acute leukemia (Rowley, 1998), we ana-
lyzed its status by FISH in all our samples. We
found that MLL was amplified in the same case 1
and in two additional cases (5 and 13) (Table 1). In
all three cases, five to seven copies of MLL were
located on a ring chromosome that was identified as
being derived from chromosome 11 (Fig. 1E). Five
of the 23 cases showed MLL rearrangements, a
relatively high frequency that is similar to the fre-
Figure 1. Molecular cytogenetic findings in acute
erythroleukemia. A: An inverted DAPI-stained meta-
phase spread of case 6 with an arrow pointing to the
cryptically altered chromosome 11. B: Spectral image of
the same metaphase cell from case 6. The arrow indi-
cates the derivative chromosome 11 from the translo-
cation t(11;19)(p11.2;q13.1). Blue and green colors cor-
respond to chromosomes 11 and 19, respectively. C:
WCP of chromosome 19 (green signal) on a partial
metaphase from case 10. Green color corresponds to
the genetic material from chromosome 19, which has
been translocated onto chromosome 11. Additional
green signals correspond to normal and derivative
chromosome 19. D: FISH assay on case 6 with telo-
meric probes from the short (green signal) and long
(red signal) arms of chromosome 19. Red signals on the
translocated chromosome 11 confirmed the involve-
ment of the long arm of chromosome 19 in t(11;19). A
normal chromosome 19 with both red and green signals
is also shown. E: FISH assay with the MLL gene probe
on a metaphase from case 1. The MLL gene probe gives
a two-color (green and red) signal, usually seen as a
yellow fusion signal. The partial metaphase shows two
ring chromosomes (arrows) with multiple (4 to 6) cop-
ies of the MLL genes that are seen as multiple spots on
the abnormal chromosomes.
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Figure 2.
quency found in AML M5a, M5b, or M4. About 40
cases of AML with amplifications of the MLL gene
have been documented thus far (Avet-Loiseau et
al., 1999; Cuthbert et al., 2000; Michaux et al.,
2000; Park et al., 2000; Streubel et al., 2000;
Mrozek et al., 2002; Schoch et al., 2002), suggesting
its important role in leukemogenesis. Other
genomic amplifications were detected: one case
with double-minute chromosomes, which were
shown to be C-MYC amplifications, and a homo-
geneously staining region (HSR) on chromosome
arm 12p. Neither C-MYC nor MLL amplifications,
nor HSRs have been reported previously in pa-
tients with ERL.
The cytogenetic rearrangements showed 51
chromosomal breakpoints that were non-randomly
distributed (Fig. 2). Chromosomes 11 and 19 were
most frequently involved in chromosomal aberra-
tions, clustering 11 and 10%, respectively, of all of
the rearrangements. The most recurrent break-
points were bands 11p15, 19q13.1, involved in four
rearrangements each; and bands 9q13, 11p11.2,
11q23, 12p13, 15q24, 16q22, 18q21, 19p13.1, and
21q11.2, involved in three rearrangements each. A
recent report of the cytogenetic profile of M7 AML
(Dastigue et al., 2002), by conventional G-banding,
shows that, despite the high complexity of the
karyotypes, the distribution of the breakpoints be-
tween the ERL and M7 subtypes of AML is rather
different both in their location and in their fre-
quency.
Molecular cytogenetic analysis of the erythroid
cell lines showed a different pattern (Table 2).
Five cell lines were established from BCR/ABL-
positive cells during the blast crisis phase of CML.
Their cytogenetic profile fits this condition: the
presence of an extra Philadelphia chromosome and
of isochromosome 17q, and trisomy 8. At the ploidy
level, all cell lines but TF-1 were tri- or tetraploid,
whereas patient samples were mostly diploid and
hypodiploid. Probably these differences were at-
tributable to the late passage status of the cell lines.
A comparison of the chromosome breakpoint pat-
tern between patients and cell lines (Fig. 2) shows
only a few common sites of recurrent breakpoints:
these were 19q13.1, 20q13.1, and 21q11.2. The
remaining breakpoints were distributed according
to a different pattern. As for the translocations, only
one was recurrent in case 21 and in the K562 cell
line, the t(12;21)(p11.2;q11.2). It was an unbal-
anced translocation and only the derivative chro-
Figure 2. Ideogram showing the breakpoints involved in structural
rearrangements in erythroleukemia. Arrowheads to the left of each
chromosome indicate breakpoints observed in the cell lines. Right of
each chromosome indicates breakpoints observed in patients. Numbers
above each chromosome are the number of breakpoints that could not
be assigned to a specific band. The left number corresponds to cell lines
and the right number corresponds to patient samples.
TABLE 2. SKY Karyotype of the Structural Rearrangements of Erythroblastoid Leukemic Cell Lines
Cell line SKY karyotype
TF-1 2n,der(Y)t(Y;3;11)(Ypter3Yq11.2::3
?::11q13311qter),der(1)t(1;8)(p36.3;q?),der(2)t(2;15)(q32;q22),del(3)(p13),del(3)(q12),der(3)(3?::14?),
der(5)t(5;19)(q12;q13.1),del(8)(p11.2),der(8)t(8;19)(q11.2;q13.1),der(12)t(10;12)(q21;q13),der(12)(3?::
12p11.2312q24::1?),der(14)(2?::14p12314qter),der(15)(15p12315q11::1?::8q1238qter),der(17)t(3;17)
(?;p11.2),der(19)t(19;19)(q?;?),der(20)t(3;20)(?;q11.2),der(22)t(2;22)(?;p12)
HEL-R 3n,der(1)t(1;5)(q21;q13),del(2)(q21),t(2;8)(p11.2;q11.2),t(6;11)(q23;q13),der(8)t(8;20)(p12;
q11.2),der(8)t(1;8)(q?;q24.1),del(9)(q13),der(9)dup(9)(q13;q34)t(9;22)(q34;q11.2),der(9)dup(9)(q13;
q34)t(9;11;19)(q34;q13;?),der(17)t(3;17)(q13;p11.2),der(19)t(10;19)(p11.2;q13.1),dup(21)(q11.2qter)
AP217 5n,t(9;22)(q34;q11.2),der(10)t(6;10)(q?;p13),i(17)(q10),der(17)t(15;17)(q?;p11.2),der(19)t(11;
19)(q13;p13.1),hsr(20)(q?)
Ku812 4n,del(9)(q21),t(9;22)(q34;q11.2),der(14)tas(14;14),del(17)(p11.2),i(17)(q10),der(17)t(17;
21)(p11.2;q11.2),der(20)t(4;20)(q12;q11.2)
LAMA84 3n,der(3)del(3)(p?)del(3)(q?),t(9;22)(q34;q11.2),der(11)t(11;16)(p11.2;?),der(17)t(11;17)(?;
p11.2),der(22)t(9;22)(q34;q11.2)
KmoE-02 3n,der(X)t(X;16)(p11.2;q12),der(1)del(1)(p22)del(1)(q25),der(1)del(1)(p13)del(1)(q?),der(1)t(1;
13)(q23;q22),der(2)t(2;9)(p23;?),del(3)(q21),der(3)t(3;21)(p12;q11.2),del(7)(p22),der(7)t(X;7)(?;
q11.2),del(12)(p12),der(16)t(1;16)(?;p?),i(17)(q10),hsr(19)(q?),der(20)t(9;20)(?;
p11.2),der(20)t(20;22)(q11.2;q11.2),der(20)t(20;22)(q13;q11.2)
K562 3n,der(5)t(5;6)(q11.2;?),dup(6)(pter3p12::p22qter),der(7)t(7;7)(p?;q?),del(9)(p12),der(9)t(9;9)(p1?3;q22),
der(10)t(3;10)(p21;q22),der(10)t(3;10;17)(?;p11.2;q22),der(12)t(12;21)(p11.2;q11.2),der(13)t(9;13)(?;13p11),
der(17)t(9;17)(?;p11.2),der(18)t(1;18)(?;q21–q22),dic(6;20)(?;p?),der(21)t(1;21)(?;p?),der(22)t(9;
22)(q34;q11.2),
der(22)t(22pter322q11.2::hsr(9q34;22q11.2))
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mosome 12 was retained in the cell, resulting in
loss of 12p and gain of chromosome 21 material. In
general, the available erythroid cell lines are not
comparable to the de novo ERL cases, most likely
because of their CML-derived origin.
This is the first report of molecular cytogenetics
and karyotype features of a large number of cases
of de novo erythroid leukemia with a complex
karyotype. The use of new molecular cytogenetic
techniques demonstrated several interesting fea-
tures of ERL: (1) Hypodiploidy and multiple un-
balanced translocations are very common, with net
losses of chromosome material; (2) we have found a
novel, cryptic translocation t(11;19) in two patients;
(3) MLL rearrangements, both as translocated or as
amplified, are frequent in the absence of exposure
to genotoxic agents; (4) the breakpoint analysis
pointed to chromosomes 11 and 19 as the most
frequently involved. This distribution of the break-
points shows a different pattern for ERL than for
other subtypes of AML. These features suggest a
characteristic genetic picture of ERL and helps
focus on a more intensive molecular study of this
disease.
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